How Much Vancomycin Dose Is Enough For The MRSA Infection in Pediatric Patients With Various Degrees of Renal Function?

Yang Wang¹, Ping Gao¹, Huanian Zhang*, Yujun Chen, Changhe Niu, Maochang Liu, Sichan Li, Qiong Xu and Qi Ye

Department of Clinical Pharmacology, Wuhan Medical & Healthcare Center for Women and Children, Hubei, China.

Abstract

Today, an increase in vancomycin dose has been proposed to ensure efficacy. However, the risk of nephrotoxicity will increase with the dose. The aim of this study was to evaluate the dosage regimens of vancomycin in pediatric patients based on pharmacokinetics/pharmacodynamics (PK/PD) and to optimize dosage individualization. Population pharmacokinetics analysis was performed on 155 Chinese children (aged 1 month to 16 years), which were divided into various renal function subpopulations. Monte Carlo simulation was carried to evaluate the efficacy and safety of vancomycin dosage regimens on each subpopulation. Compared with children with normal renal function as glomerular filtration rate (GFR) ≥ 90 mL/min·1.73 m², the clearance of vancomycin decreased by 39.4% and the half life increased 1.74 fold respectively in children with moderate renal inadequacy (30 ≤ GFR < 60 mL/min·1.73 m²). When vancomycin was administered as conventional dosage (40-60 mg·kg⁻¹·d⁻¹) to against methicillin-resistant staphylococcus aureus (MRSA) with higher MICs of 1-2 mg·L⁻¹ for children with normal renal function, the probability of efficacy target attainment (PTA) at AUC₀⁻²₄h/MIC ≥ 400 (where AUC is the area under curve and MIC is the minimum inhibitory concentration) achieved ≤ 63.64%. While vancomycin dosage exceeded 70 mg·kg⁻¹·d⁻¹ for children with normal renal function, 50 mg·kg⁻¹·d⁻¹ for mild renal inadequacy (60 ≤ GFR < 90 mL/min·1.73 m²), 30 mg·kg⁻¹·d⁻¹ for moderate renal inadequacy respectively, the PTA at trough concentration above 20 mg·L⁻¹ achieved > 20%, that not to be suggested for high risk of nephrotoxicity. Considering both efficacy and safety, the conventional vancomycin dosage is not enough and adjustable interval is narrow for pediatric patients with MIC 1-2 mg L⁻¹ MRSA infection and normal renal function.

Keywords: vancomycin, Children, Population Pharmacokinetics, Monte Carlo Simulation, Drug resistance, Nephrotoxicity.

Introduction

Vancomycin, a member of the glycopeptide antibiotics, was isolated from Streptomyces orientalis in 1957. It is still the first choice for treating methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and other Methicillin Resistant Coagulase-Negative Staphylococci (MRCNS) (1). With the increase of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (VISA and
VRSA) (2, 3), it has been widely recognized that individual use of vancomycin should be based on the pharmacokinetic / pharmacodynamic (PK / PD) theory. Vancomycin is mainly excreted by the kidneys, so its pharmacokinetic profile was significantly affected by the renal function of patients (4). Compared to adults, pharmacokinetic parameters of vancomycin in the pediatric population, neonates and infants in particular, were influenced by growth and maturational changes in renal function (5, 6). Children with different renal function are likely to have large interindividual variability in vancomycin pharmacokinetics and in whom the dosage guidelines are not clearly established. Meanwhile, it has been demonstrated that tissue penetration of vancomycin and antibacterial effect against MRSA were closely related with vancomycin trough concentration \( C_{\text{min}} \) and \( \text{AUC}_{0-24h}/\text{MIC} \) (where \( \text{AUC}_{0-24h} \) is the area under the drug concentration-time curve in a 24-h interval and MIC is the minimum inhibitory concentration).

Therefore, to ensure efficacy \( C_{\text{min}} \) and \( \text{AUC}_{0-24h}/\text{MIC} \) were suggested to maintain at 10-20 mg·L\(^{-1}\) and \( \geq 400 \), respectively (4-11). These parameters were established in adult patients and extrapolated in pediatric patients with MRSA infection (6). However, the renal function of most of the children increased compared with adults, and thus would be expected to be even less likely to achieve \( \text{AUC}_{0-24h}/\text{MIC} \geq 400 \) in serious MRSA infection (5). It is unknown whether the conventional vancomycin dosing for children with different renal function can result in an \( \text{AUC}_{0-24h}/\text{MIC} \geq 400 \). In addition, vancomycin may lead to severe concentration-dependent ototoxicity and nephrotoxicity (12). For these reasons, individualized medication is necessary for vancomycin to ensure the best clinical outcome and minimum risk, especially for geriatrics and pediatric patients. However, vancomycin pharmacokinetics in Asian children, Chinese children in particular, was rarely reported, thus restricting its individualized use. Besides, the efficacy and safety of conventional regimen needs further proof when applied into patients with different renal function. In the present study, we established a population pharmacokinetics (PPK) model in Chinese children at the first step. And then the correlation between vancomycin regimen and its clinical efficacy as well as its safety were evaluated under different bacterial resistance and renal function by using Monte Carlo Simulation (MCS) to provide a reference for vancomycin individualized therapy.

**Experimental**

**Patients and Treatment protocol**

All patients admitted from March 2009 to January 2014 in Wuhan Medical & Healthcare Center for Women and Children, Hubei, China. Patients were eligible for our study if they were diagnosed with severe pneumonia, septic arthritis, bacteremia or bacterial meningitis with MRS (including MRSA, MRSE and the other MRCNS); showed no obvious improvement of clinical signs after initiating therapy with the other antibiotics over 72 h, and drug sensitive test showed the pathogens were sensitive to vancomycin; were strict compliance with vancomycin therapy. Patients who meet the following standard were excluded from this study. whose key data were missing; whose sampling time was not clear or wrong; received treatment which may affect the vancomycin pharmacokinetics such as prolonged intermittent renal replacement therapy or high-volume haemofiltration (13, 14). Vancomycin (Eli Lilly Japan K.K, Seishin Laboratories) was given by intravenous infusion and its dosage or frequency were in line with the package insert or adjusted according to the clinical manifestation (Table 1).

The study protocol was approved by the Medical Ethics Committee of Wuhan Medical & Healthcare Center for Women and Children. The legal representative or guardian of each participant provided written informed consent before entering the study in compliance with the applicable local regulations.

**Sample Collection and analysis**

1 to 3 blood samples about 3 mL for vancomycin concentration determination were drawn from a peripheral vein of each patient after the fourth dose, and the time between dosing and sampling was recorded. Blood samples were
Vancomycin PPK analysis and dose simulation

Centrifuged and the serum was obtained; all of the serum samples were kept frozen at -20 °C until the analysis was taken.

For vancomycin analysis, 1 mL serum was loaded onto a solid phase extraction column, and eluted with 10% acetonitrile. Serum samples were analyzed for vancomycin with Agilent high performance liquid chromatography (HPLC) system and a Hypersil C<sub>18</sub> column (4.6mm×200mm, 10 μm). The mobile phase consisted of acetonitrile- potassium dihydrogen phosphate (9:91) and the flow speed was 0.8 mL/min. The detecting wavelength was 236 nm. The linear range of vancomycin in serum was 0.9-117.3 mg/L.

The limits of detection (LOD) was 0.4 mg/L; The mean recovery of vancomycin in QC samples at concentrations of 0.9, 59.1 and 117.3 mg/L were between 96.7%~101.7%, both of the intra-day and inter-day relative standard deviation (RSD) were less than 5%.

**Determination of biochemistry and MIC**

The biochemical analysis including alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin (DBIL), total bilirubin (TBIL), urea nitrogen (BUN), and creatinine (CRE) were determined using Cobas 8000 (Roche Diagnostics Ltd, Forrenstrasse, Switzerland). Glomerular filtration rate (GFR) was calculated by the modified Schwartz’s formula (15).

The MIC values were determined using the standardized agar dilution method. If more than 1 bacterium was isolated, the highest value was used as the definitive MIC.

**Data Analysis**

Software and hardware

PPK software: Phoenix® NLME program

---

**Table 1.** Baseline characteristics of patients for population pharmacokinetics modeling (n = 155, mean ± SD).

| Characteristics               | Value                          |
|-------------------------------|-------------------------------|
| **Patient Data**              |                               |
| Gender (male:female)          | 65:90                         |
| Age (months)                  | 25.86±35.22                   |
| Height (cm)                   | 79.21±25.43                   |
| Weight (kg)                   | 10.94±6.86                    |
| Body surface area (m<sup>2</sup>) | 0.48±0.23                    |
| **Laboratory parameter**      |                               |
| ALT (IU·L<sup>-1</sup>)       | 46.01±92.51                   |
| AST (IU·L<sup>-1</sup>)       | 70.35±104.03                  |
| DBIL (µmol·L<sup>-1</sup>)    | 4.58±6.41                     |
| TBIL (µmol·L<sup>-1</sup>)    | 11.19±16.85                   |
| BUN (mmol·L<sup>-1</sup>)     | 3.48±1.86                     |
| CRE (µmol·L<sup>-1</sup>)     | 33.72±17.34                   |
| GFR (mL/min·1.73m<sup>2</sup>) | 138.84±69.32                  |
| **Vancomycin dosage regimen** |                               |
| Single dose (mg·kg<sup>-1</sup>) | 14.42±3.90                   |
| Daily dose (mg·kg<sup>-1</sup>·d<sup>-1</sup>) | 40.57±8.84                  |
| Dosing interval time (hr)     | 8-24                          |

Glomerular filtration rate (GFR) was calculated with modified Schwartz formula.
(version 1.2, Pharsight Corporation, USA); MCS software: Oracle® Crystal Ball software (version 11.1.2.1.0, Oracle Corporation, USA); Computer: Dell precision® desktop computer (version T5500, Dell Inc. China) with the Windows 7 operating system.

**Population PK model development**

**Structural model**

The population PK analysis was performed using a non-linear mixed-effect model approach implemented using NLME computer program, a population pharmacokinetic model was fitted to vancomycin serum concentrations versus time data from a total of 351 samples obtained from 155 patients aged 1 month to 16 years. The first order conditional estimation method with the η-ε interaction option (FOCE L-B) was used to obtain parameter estimates. Based on previous modeling performed on other studies (16, 17) and exploratory graphical analysis, one- and two-compartment structural kinetic models with first-order elimination were evaluated. The best structural model was chosen based on an examination of the objective function value (OBJ, equal to the -2 log-likelihood value of the data) and the visual inspection of standard goodness-of-fit plots, including the individual fits.

**Error model**

The exponential model was used to describe the inter-individual variability of the PK parameters as shown in Equation 1:

\[ P_i = \theta \cdot \text{Exp}(\eta_i) \quad \text{Equ.1} \]

Where \( P_i \) is the pharmacokinetic parameter for the \( i^{th} \) individual, \( \theta \) is the population typical value of the according parameter, and \( \eta_i \) is a random variable for the \( i^{th} \) individual following a Gaussian distribution with a mean of 0 and a variance of \( \sigma^2 \).

The intra-individual variability (residual error) was evaluated using an addition model according to

\[ C_{\text{obs}} = C_{\text{pred}} + \varepsilon \quad \text{Equ. 2} \]

Where \( C_{\text{obs}} \) is the observed serum vancomycin concentration, \( C_{\text{pred}} \) is the corresponding model predicted concentration, and \( \varepsilon \) is assumed to follow a Gaussian distribution with a mean of 0 and a variance of \( \sigma^2 \).

**Covariate analyses**

Demographic variables (including gender, age, height, weight, and body surface area), hepatic and renal functions (including ALT, AST, DBIL, TBIL, BUN, CRE, GFR) of patients were tested as potential covariates for the PK parameters. Categorical covariates were incorporated using indicator variables with an exponential function. The influences of continuous covariates were included in the model using a power function. Covariates were chosen using stepwise forward selection-backward elimination with the likelihood ratio test. Because the OBJ follows a chi-square distribution, a covariate was considered significant when the addition of the covariate resulted in a decrease in the OBJ (ΔOBJ) of greater than 3.84 (\( P < 0.05; \text{df} = 1 \)), and the elimination of the covariate resulted in an increase in the OBJ (ΔOBJ) of greater than 6.63 (\( P < 0.01; \text{df} = 1 \)). After a full covariate regressive model was established, the analysis procedure was continued until only significant covariates remained in the final model.

**Model evaluation**

The PK final model was evaluated using Bootstrapping, Visual Predictive Check (VPC) and goodness-of-fit plots, including observations against population or individual predictions scatterplot, distribution of residuals. Using the final model, 1,000 bootstrap-resampled data sets from the original model group data sets were sequentially estimated. The median and 95% confidence intervals (95% CIs) (2.5th percentile and 97.5th percentile) of the parameters obtained from this step were compared with the final parameter estimates. A VPC was carried out for the final model for which 1,000 datasets were simulated.

**Groups and MCS**

According to the grade standard for renal function recommended by National Kidney Foundation (NKF-K/DOQI, 2002) (18),
155 patients were divided into three groups: normal (GFR ≥ 90 mL/min/1.73 m²), mild renal insufficiency (GFR 60-89 mL/min/1.73 m²), and moderate renal insufficiency (GFR 30-59 mL/min/1.73 m²). Patient with GFR <30 mL/min/1.73 m² or renal failure were not involved. After fixing the PK parameters and variation in the final model, the PK parameters for individuals in three groups of different renal function were obtained by using post hoc empirical Bayesian approach. The mean values and standard deviation of the parameters in different groups were calculated. Based on the previous reports (5-10, 19-22) and guidelines (4, 11), AUC_{0-24h}/MIC was chosen as the indicator of vancomycin efficacy against MRSA and AUC_{0-24h}/MIC ≥ 400 was considered effective. Vancomycin trough concentration (C_{min}) were regarded as the indicator of safety and C_{min} > 20 mg·L^{-1} indicated high risk of nephrotoxicity. Pharmacokinetic parameter was assumed following the lognormal distribution, dosage regimen, MIC and renal function of patients were setup, and then Monte Carlo simulations run for 10 000 times according to the formula (1) and (2).

Probability of target attainment (PTA) for the indicators was used to evaluate the efficacy and safety of various dosage regimens under preset scenes.

\[
\frac{AUC_{0-24h}}{MIC} = \frac{Dose}{CL \times MIC} \quad \text{Equ. 3}
\]

\[
C_{\text{min}} = \frac{x_0}{k_e \tau} (e^{-\theta_1 \tau} - 1)(1 - e^{-\theta_1 \tau})^{e^{-\theta_2 \tau}} \quad \text{Equ. 4}
\]

Where dose is vancomycin daily dose, CL is clearance, k_e is elimination rate constant, V_d is apparent volume of distribution, x_0 is single dose, T is the infusion time, τ is dosing intervals.

Statistical analyses

Descriptive statistics were expressed as the arithmetic mean ± SD unless otherwise specified. The statistical analysis was carried out using SPSS Statistics for Windows software (version 13.0) by Student’s t-test and one-way analysis of variance followed by post hoc test.

P < 0.05 was considered significant.

**Results**

**Patient characteristics**

In total, 155 patients ranging in age from 1 month to 16 years (110 patients were younger than 2 years, accounted for 71%) with 351 samples were enrolled into this study. The demographic and clinical characteristics of the patients were summarized in Table 1. The intervals between the last dosage time and sampling time were distributed over 0.5–24 h (Figure 1).

**Population Pharmacokinetics**

A one-compartment, open kinetic model with first-order elimination best described the data. Parameterisation of the final one compartment model was in terms of systemic clearance (CL) and apparent volume of distribution (V_d). This model resulted in OBJ drops of 78.6 from the comparable two-compartment model. The hypothesis test results of covariates affecting on vancomycin CL were summarized in Table 2. A summary of the full model development process is shown in Table 3 in decreasing order of the OBJ (model improvement).

In the final model, the equations by which to derive the population values for CL, V_d are as follows:

\[
\theta_{V_d} (L) = 0.558 \times \text{Weight}^{1.027}
\]

\[
\theta_{\text{CL}} (L \cdot \text{h}^{-1}) = 0.004 \times \text{Weight}^{0.858} \times (\ln \text{GFR})^{2.367}.
\]

Where Weight is given in kg, and GFR is given in mL/min·1.73m².

The parameter estimates and bootstrap confidence intervals for the final model are shown in Table 4. The typical population values of the pharmacokinetic parameters estimated in final model after normalization to the median weight of 9 kg and median GFR of 121.5 mL/min·1.73 m² in these subpopulations were as follows: The V_d was 5.33 L; the CL was 1.08 L·h^{-1} and the corresponding half-life estimate was 3.4 h. The population estimates for the final model were very similar to the median of the bootstrap replicates (relative error was within ±10%) and within the 95% confidence
interval obtained from the bootstrap analysis. VPC of the final model indicated that the model provided a reliable description of the observed data (Figure 1). The goodness-of-fit plots in Figure 2 show that the model predictions were in reasonable agreement with the observed plasma concentrations. No trend in the conditional weighted residuals versus the time-after-dose plots was observed. Most of the conditional weighted residuals were evenly distributed around zero and within an SD of ±2 of the normalized units.

**Individual pharmacokinetic parameters**

The pharmacokinetic parameters for individuals were calculated by Bayesian analysis (Table 5). Vancomycin clearance and elimination rate constant showed significant differences in the three groups (P < 0.05), indicating renal function played a critical role in vancomycin clearance. Compared with the group with normal renal function, the clearance decreased by 39.4% and elimination rate constant decreased by 42.4% (or the half life increased 1.74 fold) in patients with moderate renal insufficiency.

**Evaluation of the efficacy**

Bacterial resistance and renal function of patients under various dosage regimens were setup in advance, and then Monte Carlo

---

**Table 2. Hypothesis test results of covariates affecting on vancomycin clearance (CL).**

| Hypothesis test | OBJ | AOBJ | P-value | Comments |
|-----------------|-----|------|---------|----------|
| Basic model     | 2206.3 |     |         |          |
| If Gender affect CL ? | 2205.0 | -1.3 | >0.05 | NO |
| If Age affect CL ? | 2097.6 | -108.7 | <0.01 | YES |
| If Weight affect CL ? | 2094.0 | -112.3 | <0.01 | YES |
| If Body surface area affect CL ? | 2095.4 | -110.9 | <0.01 | YES |
| If ALT affect CL ? | 2204.8 | -1.5 | >0.05 | NO |
| If AST affect CL ? | 2204.8 | -1.5 | >0.05 | NO |
| If CRE affect CL ? | 2197.5 | -8.8 | <0.01 | YES |
| If BUN affect CL ? | 2205.6 | -0.7 | >0.05 | NO |
| If GFR affect CL ? | 2140.6 | -65.7 | <0.01 | YES |

---

**Table 3. Full model development process and statistical analysis.**

| Step | Model structure | OBJ | AOBJ | P-value | Comments |
|------|----------------|-----|------|---------|----------|
| 0    | \(V_d = \theta_{V_d} \cdot \text{Exp}(\eta_{V_d})\); \(CL = \theta_{CL} \cdot \text{Exp}(\eta_{CL})\) | 2206.3 |     |         | Basic model |
| 1    | \(V_d = \theta_{V_d} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{Exp}(\eta_{V_d})\); \(CL = \theta_{CL} \cdot \text{Exp}(\eta_{CL})\) | 2074.6 | -131.7 | < 0.01 |         |
| 2    | \(V_d = \theta_{V_d} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{Exp}(\eta_{V_d})\); \(CL = \theta_{CL} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{Exp}(\eta_{CL})\) | 1959.2 | -115.4 | < 0.01 |         |
| 3    | \(V_d = \theta_{V_d} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{Exp}(\eta_{V_d})\); \(CL = \theta_{CL} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{lnGFR}^\theta_{\text{lnGFR}} \cdot \text{Exp}(\eta_{CL})\) | 1927.3 | -31.9 | < 0.01 |         |
| 4    | \(V_d = \theta_{V_d} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{Exp}(\eta_{V_d})\); \(CL = \theta_{CL} \cdot \text{Weight}^\theta_{\text{Weight}} \cdot \text{lnGFR}^\theta_{\text{lnGFR}} \cdot \text{Exp}(\eta_{CL})\) | 1922.5 | -4.8 | < 0.05 | Full model |

\(\theta_{\text{Weight}}, \theta_{\text{lnGFR}}\) and \(\theta_{\text{Age}}\) were the fixed parameters relating to covariates; AOBJ was the change of objective function value while adding or deleting one covariate from prior model.
Vancomycin PPK analysis and dose simulation

1001 simulations run for 10,000 times according to the formula (1) and the PK parameters in Table 3. The mean value and PTA of $\text{AUC}_{0-24h}/\text{MIC}$ were obtained to evaluate the efficacy of different dosage regimens under preset scenes (Table 6). Higher PTA for $\text{AUC}_{0-24h}/\text{MIC} \geq 400$ suggested better expected efficacy. As showed in Table 6, when patients with normal renal function (GFR $\geq 90$ mL/min·1.73m²) were given vancomycin 40 mg·kg⁻¹·d⁻¹ to kill the bacteria with MIC $\leq 0.50$ mg·L⁻¹, the PTA of $\text{AUC}_{0-24h}/\text{MIC} \geq 400$ was above 85.31% in the 10,000 simulation tests, indicating a high efficiency against infection. However, with the improvement of bacterial resistance (MIC $\geq 0.75$ mg·L⁻¹), the success rate of conventional dose 40 mg·kg⁻¹·d⁻¹ was less than 51.53%, suggesting a poor expected efficacy. When the MIC reached to 1-2 mg·L⁻¹, even given a high dose of 60 mg·kg⁻¹·d⁻¹, the efficiency against infection for patients with

Table 4. Parameter estimates (standard errors, SE) and Bootstrap results for the final model.

| Parameter                                    | Final model estimate (SE) | Bootstrap estimate | Median  | 95%CI    |
|----------------------------------------------|---------------------------|--------------------|---------|---------|
| $\theta V_d$ (L) (typical value for Weight=9 kg) | 5.33(0.75)                | 5.39               | 3.528   | 7.252   |
| $\theta CL$ (L·h⁻¹) (typical value for Weight=9 kg and GFR=121.5 mL/min·1.73m²) | 1.08(0.54)                | 0.98               | 0.401   | 2.574   |
| Exponent for Weight as covariate for $V_d$   | 1.027(0.063)              | 1.018              | 0.858   | 1.183   |
| Exponent for Weight as covariate for CL      | 0.858(0.083)              | 0.852              | 0.686   | 1.022   |
| Exponent for lnGFR as covariate for CL       | 2.367(0.430)              | 2.378              | 1.503   | 3.253   |
| $\omega V_d$ (%)                             | 21.4(2.5)                 | 21.3               | 15.5    | 27.1    |
| $\omega CL$ (%)                              | 24.4(2.9)                 | 24.4               | 16.9    | 31.9    |
| $\sigma$ (mg·L⁻¹)                            | 0.52(0.052)               | 0.51               | 0.238   | 0.630   |

Figure 1. Visual predictive check for final model showing observed Vancomycin serum concentrations. The solid line shows the 50th percentile of the simulated data and the dashed lines show the 2.5th and 97.5th percentiles. The visual predictive check plots obtained after stratification by weight demonstrated a similar level of concordance between observed and simulated data.
normal renal function were below 63.64%. For patients with mild renal insufficiency, the dose of 40 mg·kg⁻¹·d⁻¹ can achieve a high success rate (PTA ≥ 83.96%) against the bacteria with MIC ≤ 0.50 mg·L⁻¹.

For patients with moderate renal insufficiency, the dose of 30 mg·kg⁻¹·d⁻¹ can achieve good efficiency (PTA ≥ 93.3%) for bacteria with MIC ≤ 0.50 mg·L⁻¹. The PTA of AUC₀⁻²₄h/MIC ≥ 400 versus MIC under different vancomycin dosage regimens were showed in Figure 3. With the increase of MIC, the success rate decreased, whereas failure happened in certain conditions.

Evaluation of the risk

Assuming that patients with different renal function were given various vancomycin dosing regimens, Monte Carlo simulations run for 10 000 times according to the formula (2) and corresponding PK parameters. The Cₘᵢₙ and PTA of Cₘᵢₙ > 20 mg·L⁻¹ were obtained to evaluate the risk of nephrotoxicity for different vancomycin regimens (Table 7). As showed in the table, the PTA of Cₘᵢₙ > 20 mg·L⁻¹ occurred when the patients with normal renal function, mild or moderate renal insufficiency received vancomycin more than 70 mg·kg⁻¹·d⁻¹, 50 mg·kg⁻¹·d⁻¹, or 30 mg·kg⁻¹·d⁻¹, respectively.
which suggested the risk of nephrotoxicity is higher than 20%. Hence, the above dose regimens should not be recommended to the corresponding populations. If the excess dose is necessary, clinician should weigh the risks and benefits and strengthen the monitoring of concentration.

**Discussion**

With the globally increase of the bacterial resistance, it has been recognized that individual use of antibiotics should be based on the PK/PD principle. Personalized medication is useful to improve efficacy, decrease resistance and minimize toxicity, especially for the drugs with severe adverse reaction (e.g., vancomycin), or population with larger variability on pharmacokinetics (e.g., geriatrics and pediatrics). FDA is advocating the use of computer simulation technology to develop clinical dosage regimen of antibiotics, design assumptions and research the effect of variables on the results, prediction and evaluation of potential benefits and risks of different regimens, in order to provide objective evidence to develop therapeutic schedule. This technique can effectively avoid the dilemmas in real clinical trial such as limited sample size and large subjective interference. MCS is an analytical method for random events or "experiments" based on artificial creation, usually obtains the probability of occurrence of a specified goal by running thousands of simulations, in order to provide reference for decision-making. Most of the published reports on antibiotic regimen optimization by using MCS were based on the PK data of healthy volunteers. Due to the difference between healthy subjects and patients, the applicability of MCS results was limited. MCS research based on the PPK is the focus of academic field in the present, which can truly reflect the disposition of drugs under clinical disease states.

In this study, the data of 155 children (aged from 1 month to 16 years) infected with MRS were used to establish a PPK model suitable for Chinese children. And then the PK parameters were obtained by Bayesian method. The mean values of CL and $V_d$ were $0.133 \pm 0.066$ L·kg$^{-1}$·h$^{-1}$ and $0.65 \pm 0.30$ L·kg$^{-1}$, respectively. Our result were similar with that of Wrishko et al. (16) (in which CL = 0.12 L·kg$^{-1}$·h$^{-1}$ and $V_d = 0.57$ L·kg$^{-1}$) and Yasuhara et al. (17) (in which CL = 0.119 L·kg$^{-1}$·h$^{-1}$ and $V_d = 0.522$ L·kg$^{-1}$). But the value of CL is faster than that reported by Marques-Minana et al. (23) (0.066 L·kg$^{-1}$·h$^{-1}$) in neonates, probably due to that, the age of the children in the present study were older. About 80%-90% of vancomycin was excreted by glomerular filtration in less than 24 h (8), some by renal tubular secretion (24), therefore renal function, especially the glomerular filtration rate (GFR) will directly affect the in-vivo elimination rate of vancomycin. Dailly et al. (25) found a positive correlation between GFR and vancomycin clearance in 70 patients suffered burns. Chen YC et al. (26) found the correlation coefficient between GFR and vancomycin clearance was

### Table 5. Pharmacokinetic parameters of subpopulation groups with various renal function status estimated with Bayesian method (n=155, mean ± SD).

| Group          | N  | CL(L·kg$^{-1}$·h$^{-1}$) | $V_d$ (L·kg$^{-1}$) | $k_e$ (h$^{-1}$) |
|----------------|----|--------------------------|---------------------|-----------------|
|                | Estimate | 95%CI          | Estimate | 95%CI          | Estimate | 95%CI          |
| GFR ≥ 90       | 111 | 0.142±0.059             | 0.131-0.153        | 0.65±0.27       | 0.60-0.70       | 0.238±0.090     | 0.221-0.255    |
| 60 ≤ GFR < 90  | 24  | 0.131±0.091             | 0.092-0.169        | 0.68±0.43       | 0.50-0.86       | 0.195±0.072b    | 0.164-0.225    |
| 30 ≤ GFR < 60  | 20  | 0.086±0.043a            | 0.066-0.106        | 0.66±0.29       | 0.53-0.80       | 0.137±0.062ab   | 0.107-0.166    |
| Total          | 155 | 0.133±0.066             | 0.123-0.144        | 0.65±0.30       | 0.61-0.70       | 0.218±0.091     | 0.204-0.233    |

P value 0.002, 0.861, 0.000

Compared with GFR ≥ 90 mL/min·1.73m$^2$ subgroup: *P < 0.05, compared with 60 ≤ GFR < 90 mL/min·1.73m$^2$ subgroup: **P < 0.05, using one-way analysis of variance followed by post hoc test.
Table 6. Simulation results of AUC<sub>0-24h</sub>/MIC of vancomycin for various dosage regimens under various preset scenes (including bacterial drug resistance and patient renal function).

| MIC of bacteria | Dosing regimen | AUC<sub>0-24h</sub>/MIC, mean (≥ 400 probability/%) |
|----------------|----------------|-----------------------------------------------|
|                |                | GFR ≥ 90 | 60 ≤ GFR < 90 | 30 ≤ GFR < 60 |
| 0.25 mg·L⁻¹    | 10mg·kg⁻¹·d⁻¹ | 330.1(25.00) | 459.6(45.84) | 559.5(70.65) |
|                | 20mg·kg⁻¹·d⁻¹ | 657.8(85.71) | 913.7(83.35) | 1138.9(98.23) |
|                | 30mg·kg⁻¹·d⁻¹ | 995.0(98.30) | 1367.1(94.78) | 1701.2(98.85) |
|                | 40mg·kg⁻¹·d⁻¹ | 1322.7(99.74) | 1825.8(98.17) | 2249.5(100) |
| 0.50 mg·L⁻¹    | 20mg·kg⁻¹·d⁻¹ | 329.6(24.66) | 456.5(46.18) | 565.4(71.45) |
|                | 30mg·kg⁻¹·d⁻¹ | 495.7(63.05) | 692.8(70.46) | 847.6(93.30) |
|                | 40mg·kg⁻¹·d⁻¹ | 659.0(85.31) | 915.1(83.96) | 1130.6(98.23) |
|                | 50mg·kg⁻¹·d⁻¹ | 828.1(94.50) | 1132.9(90.73) | 1409.7(99.57) |
| 0.75 mg·L⁻¹    | 30mg·kg⁻¹·d⁻¹ | 329.8(24.54) | 451.4(45.38) | 562.8(70.97) |
|                | 40mg·kg⁻¹·d⁻¹ | 441.1(51.53) | 605.6(63.64) | 757.0(89.02) |
|                | 50mg·kg⁻¹·d⁻¹ | 552.8(72.70) | 760.7(76.01) | 940.9(95.98) |
|                | 60mg·kg⁻¹·d⁻¹ | 662.8(85.12) | 914.8(83.60) | 1131.3(98.40) |
| 1.00 mg·L⁻¹    | 30mg·kg⁻¹·d⁻¹ | 245.6(7.31) | 340.2(28.48) | 419.6(45.34) |
|                | 40mg·kg⁻¹·d⁻¹ | 327.0(23.96) | 454.1(44.76) | 561.9(71.41) |
|                | 50mg·kg⁻¹·d⁻¹ | 413.7(45.85) | 569.8(58.93) | 702.1(85.84) |
|                | 60mg·kg⁻¹·d⁻¹ | 495.6(63.64) | 688.1(70.25) | 845.7(92.75) |
| 1.25 mg·L⁻¹    | 30mg·kg⁻¹·d⁻¹ | 196.9(2.45) | 272.9(17.92) | 339.3(27.88) |
|                | 40mg·kg⁻¹·d⁻¹ | 263.1(10.52) | 363.0(31.98) | 452.7(52.34) |
|                | 50mg·kg⁻¹·d⁻¹ | 330.0(24.44) | 458.1(46.05) | 561.7(70.94) |
|                | 60mg·kg⁻¹·d⁻¹ | 395.6(41.09) | 545.9(57.55) | 677.4(83.40) |
| 1.50 mg·L⁻¹    | 30mg·kg⁻¹·d⁻¹ | 165.7(0.93) | 229.9(11.97) | 283.3(16.02) |
|                | 40mg·kg⁻¹·d⁻¹ | 220.7(4.54) | 303.9(22.48) | 379.5(37.14) |
|                | 50mg·kg⁻¹·d⁻¹ | 275.5(12.92) | 372.7(34.00) | 469.6(55.86) |
|                | 60mg·kg⁻¹·d⁻¹ | 330.8(25.00) | 459.6(46.18) | 562.5(70.68) |
| 1.75 mg·L⁻¹    | 30mg·kg⁻¹·d⁻¹ | 141.6(0.24) | 197.9(7.69) | 243.0(9.12) |
|                | 40mg·kg⁻¹·d⁻¹ | 188.3(1.77) | 264.5(16.74) | 323.2(24.35) |
|                | 50mg·kg⁻¹·d⁻¹ | 236.3(6.34) | 324.3(25.49) | 403.6(41.80) |
|                | 60mg·kg⁻¹·d⁻¹ | 283.1(14.21) | 393.4(37.02) | 483.5(58.22) |
| 2.00 mg·L⁻¹    | 40mg·kg⁻¹·d⁻¹ | 166.1(0.76) | 229.8(12.10) | 283.3(15.87) |
|                | 50mg·kg⁻¹·d⁻¹ | 206.8(3.23) | 283.5(19.11) | 350.8(30.38) |
|                | 60mg·kg⁻¹·d⁻¹ | 248.0(8.15) | 343.1(28.66) | 424.8(46.94) |
|                | 70mg·kg⁻¹·d⁻¹ | 287.0(15.01) | 399.4(37.27) | 493.5(59.78) |

A total of 10 000 virtual pediatric patients were simulated at each regimen.
Vancomycin PPK analysis and dose simulation

84.65% in 65 patients infected with MRSA. Many vancomycin PPK studies also found various covariates which indirectly reflect the GFR such as CRE (27), Ccr (28), or cysteine proteinase inhibitor in serum c (Cystatin c) (26, 29) were significant correlated with vancomycin clearance. Modified Schwartz’s formula (15) was used to calculate GFR in children with this study and it was successfully integrated into the final model, well elaborated the quantitative relationship between GFR and vancomycin clearance. After grouping according to NKF-K/DOQI standard, we found vancomycin clearance and elimination rate constant in children with $30 \leq \text{GFR} < 60 \text{ mL/min}\cdot1.73\text{m}^2$ decreased by 39.4% and 42.4% compared with the children with GFR $\geq 90 \text{ mL/min}\cdot1.73\text{m}^2$, which proved once again the necessary of adjustment for vancomycin dosage.

After establishing the vancomycin PPK model and obtaining the PK parameters in patients with different renal function, a large sample (10 000 cases) simulation “experiment” was conducted by using MCS to explore the efficacy and safety of various dosage regimen under different preset scenes. The correlation between vancomycin antimicrobial effect against MRSA and $\frac{\text{AUC}_{0-24h}}{\text{MIC}}$ has been reported since 90’s of the last century in animal models (7, 8). Subsequently, a number of large samples of human PK/PD studies (5, 9, 10) confirmed that vancomycin organizational penetration and anti-infection is optimal when its $\frac{\text{AUC}_{0-24h}}{\text{MIC}}$ was above 400. Current United States infectious disease society (IDSA) (4, 11) and Chinese expert consensus recommends that $\frac{\text{AUC}_{0-24h}}{\text{MIC}} \geq 400$ should be regarded as the target indicator. Our MCS results indicated that the dose of 40mg·kg$^{-1}$·d$^{-1}$ was effective against MRSA strains with MIC $\leq 0.50$ mg·L$^{-1}$ (PTA of $\frac{\text{AUC}_{0-24h}}{\text{MIC}} \geq 400$ was $\geq 85.31\%$) in patients with normal renal function. But this dosage regime may fail to kill the bacteria with MIC $\geq 0.75$ mg·L$^{-1}$ (PTA $\leq 51.53\%$). In that case, a larger dose was needed. For MRSA infection with MIC 1-2 mg·L$^{-1}$, the success rate is not enough (63.64%) even given a dose of 60mg·kg$^{-1}$·d$^{-1}$. In 2006, United States Clinical Laboratory Standardization Association (CLSI) reduced the susceptibility breakpoint of vancomycin from 4 to 2 mg·L$^{-1}$ (11, 30),

![Figure 3](image-url)

**Figure 3.** Probabilities of achieving $\frac{\text{AUC}_{0-24h}}{\text{MIC}} \geq 400$ target for various dosage regimens of vancomycin and various MICs. (A) The GFR $\geq 90$ mL/min·1.73m$^2$ subgroup. (B) The $60 \leq \text{GFR} < 90$ mL/min·1.73m$^2$ subgroup. (C) The $30 \leq \text{GFR} < 60$ mL/min·1.73m$^2$ subgroup.
whereas our simulation results indicated that the conventional doses of 40-60 mg·kg⁻¹·d⁻¹ is only effective for MRSA with MIC ≤ 1 mg·L⁻¹ but inadequate for MRSA with MIC 1-2 mg·L⁻¹. Eiland et al. (31) analyzed the vancomycin TDM results of 295 children and found vancomycin given at 40-60 mg·kg⁻¹·d⁻¹ was difficult to achieve effective target trough concentration (10-20 mg·L⁻¹). They calculated using a formula and concluded that 70 mg·kg⁻¹·d⁻¹ was needed for patients with normal renal function to achieve the target trough concentration of 10 mg·L⁻¹. Giachetto et al. (32) also observed that the probability of AUC₀-2₄h/MIC ≥ 400 is only 50% even given vancomycin 39.92 mg·kg⁻¹·d⁻¹ for MRSA strains with MIC 1 mg·L⁻¹. Frymoyer et al. (33) suggested that the probability of AUC₀-2₄h > 400 will be over 90% when vancomycin trough concentration was at least 10 mg·L⁻¹. That is, vancomycin trough concentration may not need to reach 10 mg·L⁻¹ for MRSA strains with MIC ≤ 1 mg·L⁻¹, whereas for MRSA strains with MIC 1-2 mg·L⁻¹ the concentration should be more than 10 mg·L⁻¹ which was difficult to achieve routine dose. Therefore, supernormal dosage is permissible when the bacterial resistance is increased in order to ensure clinical efficacy. However, the risk of adverse drug reaction will increase with the dose. Even though the ototoxicity is rarely reported after the purity of vancomycin was improved, many toxicologic studies have demonstrated that vancomycin nephrotoxicity sharply increased when its trough concentration was above 20 mg·L⁻¹ (19-22), especially for co-administration with nephrotoxic drugs such as aminoglycoside (4). Our simulation results indicated that the probability of Cₘᵦₘ > 20 mg·L⁻¹ will be more than 20% when vancomycin dose is 70, 50, and 30 mg·kg⁻¹·d⁻¹ respective for patients with GFR ≥ 90 mL/min·1.73 m², 60 ≤ GFR < 90 mL/min·1.73 m² and 30 ≤ GFR < 60 mL/min·1.73 m². In that cases, the probability of nephrotoxic were greater, so the corresponding dose was not recommended. Combined with the simulation results of efficacy and safety,

| Dosing regimen         | GFR ≥ 90 | 60 ≤ GFR < 90 | 30 ≤ GFR < 60 |
|------------------------|----------|---------------|---------------|
| 10 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 1.59(0.00) | 2.57(0.18) | 4.30(0.50) |
| 20 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 3.28(0.17) | 5.14(1.88) | 8.65(6.96) |
| 30 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 4.93(1.09) | 7.63(5.74) | 12.72(17.5) |
| 30 mg·kg⁻¹·d⁻¹, tid, 2-h infusion | 5.42(1.58) | 8.41(1.14) | 13.81(19.42) |
| 40 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 6.58(3.40) | 10.31(11.37) | 17.28(30.10) |
| 40 mg·kg⁻¹·d⁻¹, tid, 2-h infusion | 7.21(3.87) | 11.22(13.54) | 18.08(32.20) |
| 50 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 8.18(6.44) | 12.94(17.88) | 21.62(40.97) |
| 50 mg·kg⁻¹·d⁻¹, tid, 2-h infusion | 9.17(8.29) | 13.95(20.53) | 22.59(44.00) |
| 60 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 9.69(9.73) | 15.66(24.62) | 25.57(50.11) |
| 60 mg·kg⁻¹·d⁻¹, tid, 2-h infusion | 10.82(12.34) | 16.89(27.92) | 27.15(53.64) |
| 70 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 11.58(14.54) | 17.95(29.94) | 30.19(59.00) |
| 70 mg·kg⁻¹·d⁻¹, tid, 2-h infusion | 12.73(17.61) | 19.38(34.17) | 31.26(61.13) |
| 80 mg·kg⁻¹·d⁻¹, tid, 1-h infusion | 13.22(19.24) | 20.80(35.83) | 34.47(65.05) |
| 80 mg·kg⁻¹·d⁻¹, tid, 2-h infusion | 14.55(22.70) | 22.38(40.26) | 36.32(67.56) |

A total of 10,000 virtual pediatric patients were simulated at each regimen.
Vancomycin PPK analysis and dose simulation

The dose range of vancomycin for children with various degrees of renal function is obtained (Figure 4). We concluded that the range of vancomycin dose is narrow for MRSA strains with MIC 1-2 mg·L⁻¹; hence, the treatment will be more difficult and the cure rate is not high. Since the MRSA strains with MIC 1-2 mg·L⁻¹ are prone to mutate into heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA), producing offspring MIC ≥ 4 mg·L⁻¹ resistant subpopulation (30), which should be paid attention and a better way to fight infection was necessary. For this type of strain, the clinicians can increase the dose of vancomycin under blood concentrations monitoring and toxicity monitoring, or combine vancomycin with rifampicin (34) or fosfomycin (35), or replace with lower nephrotoxic drugs such as linezolid, daptomycin, and teicoplanin for the patients with moderate or even worse renal function.

The present study suggested that individualized dosing regimen of vancomycin should be developed in accordance with bacterial resistance and renal function of the patients, and fully considering the pros and cons in order to ensure the efficacy and safety of antibiotic therapy. According to the simulation results, 40-70, 30-50, 10-30 mg·kg⁻¹·d⁻¹ vancomycin daily dose for MIC ≤ 1 mg·L⁻¹ MRSA infection treatment is adapted to pediatric patients with GFR ≥ 90, 60 ≤ GFR < 90 and 30 ≤ GFR < 60 mL/min·1.73m², respectively. And the adjustable dosage interval of vancomycin is narrow for treating MIC 1-2 mg·L⁻¹ MRSA infection. The limitation of the study is the number of the patients with renal insufficiency is small, so fitting errors may exist for the pharmacokinetic characteristics of such population. We will collect more patients in the future to in-depth explore the regularity of vancomycin PK/PD in Asian children.

Figure 4. The dose range of vancomycin for children with different renal function. (A) for bacteria with MIC < 1 mg·L⁻¹. (B) for bacteria with MIC 1-2 mg·L⁻¹.

Compliance with Ethical Standards

Funding: This work was funded by The Key Project of Science and Technology of Wuhan (2013060602010258) and The National Futang Fund for Children’s Medicine Development (2015 No.33).

Conflicts of interest: All authors have no potential conflicts of interest to declare.

Ethical approval: All procedures in this study were carried out in accordance with the 1964 Helsinki declaration and its amendments and the ethical committee or institutional review board which approved the study.

Informed consent: Written informed consent was obtained from the legal representative or guardian of each patient when they began treatment but was not required for the present analyses because this was a retrospective study.
Acknowledgment

This work was funded by The Key Project of Science and Technology of Wuhan (20130606020101258) and The National Futang Fund for Children’s Medicine Development (2015 No.33).

References

(1) Rubinstein E, and Keynan Y. Vancomycin Revisited - 60 Years Later. Front. Public Health. (2014) 2: 217.
(2) Chaiwongkar Johan S, Pramooythin P, Suwanratat N, Bankowski MJ, Koyamatsu T, Seifried SE and Bello EF. A Report on the First Case of Vancomycin-Intermediate Staphylococcus Aureus (Visa) in Hawai’i. Hawaii Med. J. (2011) 70: 233-6.
(3) Hakim ST, Arshed S, Iqbal M and Javaid S. Vancomycin Sensitivity of Staphylococcus Aureus Isolates from Hospital Patients in Karachi, Pakistan. Libyan J. Med. (2007) 2: 176-9.
(4) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, M JR, Talan DA and Chambers HF. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary. Clin. Infect. Dis. (2011) 52: 285-92.
(5) Frymoyer A, Hersh AL, Benet LZ and Guglielmo BJ. Current Recommended Dosing of Vancomycin for Children with Invasive Methicillin-Resistant Staphylococcus Aureus Infections Is Inadequate. Pediatr. Infect. Dis. J. (2009) 28: 398-402.
(6) Bhongsiarn J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB and Sherwin CM. Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance? J. Clin. Pharmacol. (2016) 56: 528-40.
(7) Craig WA. Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men. Clin. Infect. Dis. (1998) 26: 1-10; quiz 11-12.
(8) Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clin. Infect. Dis. (2006) 42 Suppl 1: S35-39.
(9) Moise-Broder PA, Forrest A, Birmingham MC and Schentag JJ. Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus Aureus Lower Respiratory Tract Infections. Clin. Pharmacokinet. (2004) 43: 925-42.
(10) Kullar R, Davis SL, Levine DP and Rybak MJ. Impact of Vancomycin Exposure on Outcomes in Patients with Methicillin-Resistant Staphylococcus Aureus Bacteremia: Support for Consensus Guidelines Suggested Targets. Clin. Infect. Dis. (2011) 52: 975-81.
(11) Rybak MJ, Lomaestro BM, Rotschafer JC, Moellinger RC, Craig WA, Billeter M, Dalovisio JR, and Levine DP. Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. (2009) 49: 325-7.
(12) Marsot A, Boulamery A, Bruguerolle B and Simon N. Vancomycin: A Review of Population Pharmacokinetic Analyses. Clin. Pharmacokinet. (2012) 51: 1-13.
(13) Lewis SJ and Mueller BA. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. SAGE Open Med. (2018) 6: 1-10.
(14) Escobar L, Andresen M, Downey P, Gai MN, Regueira T, Borquez T, Lipman J and Roberts JA. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Int. J. Antimicrob. Agents. (2014) 44: 163-7.
(15) Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA and Furth SL. New Equations to Estimate Gfr in Children with Ckd. J. Am. Soc. Nephrol. (2009) 20: 629-637.
(16) Wrischk RE, Levine M, Khoo D, Abbott P and Hamilton D. Vancomycin Pharmacokinetics and Bayesian Estimation in Pediatric Patients. Ther Drug Monit. (2000) 22: 522-31.
(17) Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T Yano Y and Hori R. Population Pharmacokinetics of Vancomycin in Japanese Pediatric Patients. Ther Drug Monit. (1998) 20: 612-8.
(18) Hogg RJ, Furth S, Llemly KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS and National Kidney Foundation’s Kidney Disease Outcomes Quality I. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification, and Stratification. Pediatrics. (2003) 111: 1416-1421.
(19) Lodise TP, Patel N and Lomaestro BM. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin. Infect. Dis. (2009) 49: 507-14.
(20) Pritchard L, Baker C, Leggett J, Schdev P, Brown A and Bayley KB. Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity. Am. J. Med. (2010) 123: 1143-9.
(21) Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA and Kett DH. Incidence of Nephrotoxicity and Association with Vancomycin Use in Intensive Care Unit Patients with Pneumonia: Retrospective Analysis of the Impact-Hap Database. Clin. Ther. (2012) 34: 149-57.
(22) Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A and Chastre J. Linezolid in Methicillin-Resistant...
Staphylococcus Aureus Nosocomial Pneumonia: A Randomized, Controlled Study. *Clin. Infect. Dis.* (2012) 54: 621-629.

(23) Marques-Minana MR, Saadeddin A and Peris JE. Population Pharmacokinetic Analysis of Vancomycin in Neonates. A New Proposal of Initial Dosage Guideline. *Br. J. Clin. Pharmacol.* (2010) 70: 713-20.

(24) Pea F, Porreca L, Baraldo M and Furlanut M. High Vancomycin Dosage Regimens Required by Intensive Care Unit Patients Cotreated with Drugs to Improve Haemodynamics Following Cardiac Surgical Procedures. *J. Antimicrob. Chemother.* (2000) 45: 329-35.

(25) Dailly E, Le Floch R, Deslandes G, Pannier M and Jolliet P. Influence of Glomerular Filtration Rate on the Clearance of Vancomycin Administered by Continuous Infusion in Burn Patients. *Int. J. Antimicrob. Agents* (2008) 31: 537-9.

(26) Chen YC, Feng JF, Li B, Zhang L and Yang YW. Estimation of Safe and Effective Dose of Vancomycin in Mrsa-Infected Patients Using Serum Cystatin C Concentrations. *Int. J. Clin. Pharmacol. Ther.* (2013) 51: 161-9.

(27) Lamarre P, Lebel D and Ducharme MP. A Population Pharmacokinetic Model for Vancomycin in Pediatric Patients and Its Predictive Value in a Naive Population. *Antimicrob. Agents Chemother.* (2000) 44: 278-82.

(28) Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesnes F, Storme T, Baruchel A and Jacqz-Aigrain E. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease. *Antimicrob. Agents Chemother.* (2014) 58: 3191-9.

(29) Akihiro T, Tetsuya A, Takashi O, Katsuya S, Tatsuya N, Tomoyoshi I, Mitsuharu M, Yuji K, and Hiroaki A. Population Pharmacokinetic Analysis of Vancomycin Using Serum Cystatin C as a Marker of Renal Function. *Antimicrob. Agents Chemother.* (2010) 54: 778-82.

(30) Aminzadeh Z, Yadegarynia D, Fatemi A, Tahmasb Trehkordi E and Azad Armati S. Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus Aureus Infections; Is There Difference in Mortality between Patients? *Jundishapur J. Microbiol.* (2014) 7: e12831.

(31) Eiland LS, English TM and Eiland EH. Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients. *Ann. Pharmacother.* (2011) 45: 582-9.

(32) Giachetto GA, Telechea HM, Noelia S, Mireille O, Luciana N and Amanda M. Vancomycin Pharmacokinetic-Pharmacodynamic Parameters to Optimize Dosage Administration in Critically Ill Children. *Pediatr. Crit. Care. Med.* (2011) 12: 250-4.

(33) Adam F, Hersh AL, El-Komy MH, Shabnam G, Felice S, Drover DR, and Krisa VM. Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates. *Antimicrob. Agents. Chemother.* (2014) 58: 6454-61.

(34) Tang HJ, Chen CC, Ko WC, Yu WL, Chiang SR and Chuang YC. *In-vitro* Efficacy of Antimicrobial Agents against High-Inoculum or Biofilm-Embedded Meticillin-Resistant Staphylococcus Aureus with Vancomycin Minimal Inhibitory Concentrations Equal to 2 Mug/Ml (Va2-Mrsa). *Int. J. Antimicrob. Agents* (2011) 38: 46-51.

(35) Shi J, Mao NF, Wang L, Zhang HB, Chen Q, Liu H, Tang X, Jin T, Zhu CT, Li FB, Sun LH, Xu XM and Xu YQ. Efficacy of Combined Vancomycin and Fosfomycin against Meticillin-Resistant Staphylococcus Aureus in Biofilms *in-vivo*. *PLoS One.* (2014) 9: e113133.

This article is available online at http://www.ijpr.ir